USP CAR-T Therapy Cuts Liver Fibrosis in Mice | AcademicJobs
USP researchers pioneer in vivo CAR-T therapy using lipid nanoparticles to combat hepatic fibrosis in MASH mouse models, restoring liver function.
No reviews yet. Be the first to rate Bruno!
Bruno Cogliati is a Professor Associado in the Department of Pathology at the Faculdade de Medicina Veterinária e Zootecnia (FMVZ) of the Universidade de São Paulo (USP). He earned his veterinary medicine degree from FMVZ-USP in 2005, completed a doctorate in Experimental and Comparative Pathology at FMVZ-USP in 2010, and undertook postdoctoral training in experimental gastroenterology at the Faculdade de Medicina of USP in 2011.
His research centers on experimental and comparative pathology, with emphasis on intercellular communication in in vitro and in vivo models of hepatic fibrosis and cirrhosis, metabolic dysfunction-associated steatotic liver disease (MASLD/MASH), hepatocarcinogenesis, and comparative studies of hepatic neoplasms in dogs and cats. Cogliati has served as president of the International Cooperation Office (CCInt) at FMVZ-USP and as vice-coordinator of the Postgraduate Program in Experimental and Comparative Pathology (CAPES grade 6). He is an affiliated member of the Academia Brasileira de Ciências in the Agrarian Sciences area. In 2019, he received the PRÊMIO IMPACTO CIENTÍFICO (PIC) from FMVZ-USP (1st place, Department of Pathology) and supervised the best oral presentation at the 27th SIICUSP.
USP researchers pioneer in vivo CAR-T therapy using lipid nanoparticles to combat hepatic fibrosis in MASH mouse models, restoring liver function.